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Abstract: Transdermal administration of primaquine has been found to produce radical
cure against sporozoite induced Plasmodium cynomolgi B infection in rhesus monkeys. For-
mulation containing 7mg/kg primaquine (base) was curative in 12 out of 13 rhesus monkeys
as no relapse occurred during the observation period of 100 days.
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INTR ODUCTION
Primaquine is the only 8-aminoquinoline drug in clinical use for treatment of relapses of
Plasmodium vivax infections. The drug is usually administered for 7-14 consecutive days to
achieve radical cure and is known to produce adverse side-effect including gastrointestinal
distress, nausea and methaemoglobinemia with cyanosis (Clyde, 1981). Transdermal drug
delivery as an alternative mean of drug administration has gained, in recent years, high pa-
tient acceptance in many clinical conditions and the advantages of delivering drugs across the
skin for systemic circulation are well-documented (Price et at., 1981; Laufer et al, 1983;
Karim, 1985; Shaw, 1983). This mode of drug administration can eliminate some of the side-
effects associated with gastrointestinal absorption and also avoid deactivation of the drug by
first-pass metabolism.
Recent studies on the use of transdermal route for drug delivery in malaria are limited
to the preparations with blood schizontocidal agents like sodium artesunate and artemether
(Xuan et al., 1988, 1990), and artelinic acid (Klayman et al., 1991). Klayman et at., (1991)
recorded per cent curative and prophylactic efficacy with transdermal preparations of
artelinic acid against blood stages of P. berghei in mice. This is the first report on the suc-
cessful use of transdermal preparation of tissue schizontocidal drug primaquine to achieve
radical cure against sporozoite induced P. cynomolgi infection in rhesus monkeys.
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Plasmodium cynomolgi bastianelli strain has been used for the present study. The
sporozoite induced infections of P. cynomolgi B in rhesus monkeys are being maintained
routinely by cyclic transmission through Anopheles stephensi (Puri et at., 1989).
Animals:
The rhesus monkeys (Macaca mulatto} were obtained from approved contractors and
quarantined for one month before experimentation. The monkeys were fed on pellets, bread,
seasonal fruits and water was provided ad libitum. During quarantine, monkeys were tuber-
culin tested and their blood smears were examined 2-3 times to ensure absence of any
natural blood protozoan infections.
Preparation of primaquine transdermal tapes
Transdermal tapes were prepared from 1 gm of the matrix filled in molds of 25.6 mm
diameter and 3 mmdepth. The molds were prepared from polypropylene sheets by hot press
technique using a die of appropriate size. All the molds so prepared had constant surface
area (5 cm2) available for drug release. The matrix was prepared according to method of Jain
et al. (1992) by dissolving 65.5% of polyvinyl pyrolidone and 17% of polyethylene glycol in a
mixture of 1:1 dichloromethane and ethyl alcohol by aid of slight heat followed by removing
the solvent. To the residue, the required amount of primaquine diphosphate and 0.5% urea in
17% propylene glycol were homogenously mixed. Each mold is uniformaly filled with 1 gm
of this matrix and kept under vacuumfor 2-3 hrs to remove entrapped air if any. On the sur-
face of matrix in each mold, 0.1 gm of azone was uniformaly spread. The matrix was subseq-
quently allowed to cure for 24 hrs under vacuumat room temperature.
Assay for anti-relapse activity:
For efficacy tests, the monkeys were anaesthetized with 5 mg/kg ketamin
hydrochloride (i.m.) and their upper arm was carefully shaved to avoid any cuts or abrasions
on the skin. The bare skin was cleaned with alcohol before applying the matrix filled molds
containing 1.75 mg base/kg to 7.00 mg base/kg primaquine. The molds were kept in contact
with monkey's skin by wrapping three-four layers of adhesive tape around the arm. The
molds were applied to the infected monkeys when parasitaemia level of approximately
5000/mm3 was attained after sporozoite induced infections. These tapes were kept in place
for 7 days. The anti-relapse activity of primaquine was also established via oral route in 4
monkeys which were administered 1 mg (base)/kg drug for 7 days.
The test protocol for anti relapse activity established at this institute was followed (Dut-
ta and Puri, 1988). Chloroquine at a dose of 5 mg (base)/kg x 7 days was concurrently ad-
ministered as the companion blood schizontocide to eliminate blood stage parasites. Giemsa
stained blood smears from the experimental monkeys were observed to record the occurrenc-
ce of relapse. If there was no relapse for 100 days after the last chloroquine dose, the
monkeys were taken as cured (Dutta and Puri, 1988).
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RESULT AND DISCUSSION
Primaquine administered orally at 1 mg/kg x 7 days, has been found to produce
radical cure against sporozoite induced P. cynomolgi B infection in 4/4 rhesus monkeys. This
is in agreement with our earlier report (Dutta and Puri, 1988). Transdermal formulation of
primaquine was evaluated for radical curative activity at 4 dose levels (1.75-7.00 mg base/kg)
(Table-1). The tapes containing primaquine diphosphate equivalent to 1.75 mg base/kg were
not curative in any of the four monkeys. The tapes containing drug equivalent to 3.50 mg/kg
protected 1 out of 4 experimental monkeys. The tapes containing 5.25 mg base/kg prima-
quine protected 5 out of 7 monkeys (cure rate 71.43%), while the tapes containing 7 mg
base/kg primaquine protected 12 out of 13 monkeys thus giving a cure rate of 92.3%. One of
the 13 monkeys which was not protected with the highest dose, showed a delayed relapse on
day 36. Four monkeys applied with placebo tapes (without primaquine), relapsed between
day ll-19. The log-dose probit analysis of the present data gave the ED50 and ED95 values of
4.38 mg/kg and 6.65 mg/kg respectively.
The present study thus establishes that primaquine is active by transdermal route as an
anti-relapse drug. Transdermal primaquine formulation is likely to enhance the dose com-
pliance at it would eliminate the need of repeated drug intake and avoid gastric irritation.
Table 1. Anti-relapse activity of primaquine transdermal tape against
sporozoite induced Plasmodium cynomolgi B infection in
rhesus monkeys.
No. of Relapse if any No of
Primaquine* monkeys - monkeys**
treated No. of Days after protected (%)
mnnlrpw last dose
monkeys of chloroquine
0.0 4 4 ll,14,14,19 Nil (0%)
1-75 4 4 13,15,17,18 Nil (0%)
3-50 4 3 17,17,19 1 (25%)
5-25 7 2 18,22 5 (71.43%)
7.00 13 1 36 12 (92.3%)
Pri maquine
1.00mg/kgx 7 4 4 (100%)
days (oral)
* The tape was applied on monkey's fore arm for 7 days and
chloroquine 5 rag base/kgx 7 days was administered orally.
** No relapse observed till 100 days after last chloroquine dose.
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